MedTrace Logo

The Serotonin Transporter Availability for Prognosing Major Depressive Disorder (MDD) Treatment and Detecting MDD

NCT02473783 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2018-01-19

Study results available
· View outcomes & findings →

Summary

Objectives:

1. To evaluate the relationship between improvement of Hamilton Depression Rating Scale (HAMD) score and basal SERT availability (binding potential) for the prognosis of MDD subjects being treated with Sertraline HCl
2. To evaluate the SERT availability by means of I-123-ADAM SPECT imaging study for assisting in detecting MDD
3. To evaluate the relationship between basal HAMD score and basal SERT availability for MDD subjects
4. To evaluate the relationship between basal HAMD somatic subscale score and basal SERT availability for MDD subjects
5. To evaluate the relationship between change of SERT availability and change of HAMD score for MDD patients being treated with Sertraline HCl

Conditions

Interventions

DRUG

Sertraline HCl

The regimen of Sertraline HCl will be administered with starting dose from minimum 25 mg/day for 1 week and maintenance dose of at least 50 mg/day up to 200 mg/day for the rest of 5 weeks.

OTHER

I-123-ADAM SPECT

The subjects underwent the SPECT scan after I-123-ADAM (185 MBq, 5mCi) IV injection.

Sponsors & Collaborators

  • National Atomic Research Institute, Taiwan

    collaborator OTHER

  • Tri-Service General Hospital

    lead OTHER

Principal Investigators

  • Chin-Bin Yeh, M.D., Ph.D. · Tri-Service General Hospital

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2012-11-30
Completion
2012-11-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02473783 on ClinicalTrials.gov